Highway Pharmaceuticals is a clinical-stage biotechnology company focused on reformulating and repositioning effective but dangerous generics to make safer, extended-release versions of those drugs.

Our initial therapeutic is intended to act as a extended-release form of cyclosporine, safer and easier to use than the original form. Our initial indication is chronic spontaneous urticaria (CSU), a condition in which patients suffer from chronic, recurrent hives for months at a time. We are also exploring other autoimmune and neurodegenerative indications for extended-release cyclosporine.

Our advisors are:

Clinical: Marcus Maurer, MD, author of the international guidelines on treating CSU and Director of the Allergy-Centrum-Charité at the Charité University Medicine in Berlin, the largest international center devoted to allergic diseases.

Patent: Brenda Jarrell, PhD, JD, chair of Choate’s Intellectual Property and Life Sciences Group.

Scientific: Ethan Lerner, MD, PhD, associate professor of itch at Harvard Medical School.

The President of the company is Trevor Klee, and we are based in Boston, Massachusetts.

If you’re interested, please get in touch.